A Double-blind Study of Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan in the Treatment of Acute Migraine

1996 ◽  
Vol 53 (2) ◽  
pp. 180-184 ◽  
Author(s):  
P. Winner ◽  
O. Ricalde ◽  
B. Le Force ◽  
J. Saper ◽  
B. Margul
Keyword(s):  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Subcutaneous Sumatriptan

Treatment of Acute Migraine Attack With Diclofenac Sodium: A Double-Blind Study

1992 ◽  
Vol 32 (2) ◽  
pp. 98-100 ◽  
Author(s):  
George N. Karachalios ◽  
Adroniki Fotiadou ◽  
Nickolaos Chrisikos ◽  
Alexandros Karabetsos ◽  
Kyriakos Kehagioglou
Keyword(s):  
Migraine Attack ◽  
Diclofenac Sodium ◽  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Acute Migraine Attack

Flunarizine (10 and 20 mg) i.v. Versus Placebo in the Treatment of Acute Migraine Attacks: A Multi-Centre Double-Blind Study

Cephalalgia ◽  
1990 ◽  
Vol 10 (2) ◽  
pp. 77-81 ◽  
Author(s):  
Volker Pfaffenrath ◽  
Wolfgang Oestreich ◽  
Wolfgang Haase
Keyword(s):  
Blood Pressure ◽  
Visual Analogue Scale ◽  
Drug Administration ◽  
Analogue Scale ◽  
Blind Study ◽  
Response To Treatment ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Suitable Alternative

In a multi-centre, randomized double-blind study, the effect and tolerance of 10 and 20 mg flunarizine i.v. versus placebo was tested on 102 migraineurs with acute migraine attacks with and/or without aura. Thirty-seven patients received 10 mg flunarizine, 32 received 20 mg and 33 received placebo. The groups were comparable. Response to treatment was defined as pain reduction of at least 50% within 60 min on a visual analogue scale after i.v. drug administration. This effect was noted on 59.4% with 20 mg flunarizine, on 24.3% with 10 mg flunarizine and on 30.3% with placebo. The tolerance of flunarizine i.v. was similar to placebo. Blood pressure and pulse rate were not affected by flunarizine. All in all, 20 mg flunarizine i.v. appeared to be a suitable alternative for treatment of acute migraine attacks.

A Double-Blind Study of Ibuprofen Versus Placebo in the Treatment of Acute Migraine Attacks

Cephalalgia ◽  
1992 ◽  
Vol 12 (3) ◽  
pp. 169-171 ◽  
Author(s):  
Reidar Kloster ◽  
Knut Nestvold ◽  
Steinar T Vilming
Keyword(s):  
Side Effects ◽  
Initial Dose ◽  
Acute Treatment ◽  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Inflammatory Drug ◽  
Anti Inflammatory

The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine. Twenty-five patients completed a double-blind placebo-controlled multicrossover trial. The initial dose of ibuprofen was 1200 mg. Six migraine attacks were randomly treated in each patient, three with ibuprofen and three with placebo. The results indicated a statistically significant reduction in the duration of the migraine attacks and also a statistically significant reduction in the severity of headache and nausea in the ibuprofen-treated attacks. The use of additional medication was significantly reduced in the ibuprofen-treated attacks (25.6% vs 57.5%), No serious side effects were reported. Ibuprofen is valuable in the treatment of acute migraine attacks.

Double-Blind Study of Naproxen vs Placebo in the Treatment of Acute Migraine Attacks

Cephalalgia ◽  
1989 ◽  
Vol 9 (1) ◽  
pp. 29-32 ◽  
Author(s):  
P. G. Andersson ◽  
H. H. Hinge ◽  
O. Johansen ◽  
C. U. Andersen ◽  
A. Lademann ◽  
...  
Keyword(s):  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document